Sreeja Dattachoudhury1, Renu Sharma1, Atul Kumar1, Bithiah Grace Jaganathan2. 1. Stem Cells and Cancer Biology Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India. 2. Stem Cells and Cancer Biology Research Group, Department of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati, India, bithiahgj@iitg.ac.in.
Abstract
INTRODUCTION: Metastatic breast cancer has poor prognosis due to limited therapeutic options. Protein kinase dysregulations have a major role in breast cancer progression and metastasis. In this study, we investigated the anti-cancer activity of sorafenib, a multikinase inhibitor, which targets receptor tyrosine kinases in breast cancer. Although treatment with sorafenib has increased the patient survival and inhibited metastatic migration in hepatocellular carcinoma, its role in breast cancer migration, metastasis, and intracellular signaling modulation is unknown. METHODS: Breast cancer cell lines MCF7 and MDA-MB-231 were treated with sorafenib and its effect on proliferation, migration, invasion and gene expression was analyzed. RESULTS: We found that sorafenib has an anti-proliferative and cytotoxic effect on breast cancer cells. Importantly, sorafenib inhibited the migration and invasion of breast cancer cells in vitro. Mechanistically, sorafenib increased mitochondrial superoxide production, suppressed breast cancer stem cell self-renewal, inhibited epithelial mesenchymal transition and ERK signaling. CONCLUSION: Thus, sorafenib has anti-cancer activity against breast cancer cells and could improve the survival of breast cancer patients by inhibiting their invasive and metastatic properties.
INTRODUCTION: Metastatic breast cancer has poor prognosis due to limited therapeutic options. Protein kinase dysregulations have a major role in breast cancer progression and metastasis. In this study, we investigated the anti-cancer activity of sorafenib, a multikinase inhibitor, which targets receptor tyrosine kinases in breast cancer. Although treatment with sorafenib has increased the patient survival and inhibited metastatic migration in hepatocellular carcinoma, its role in breast cancer migration, metastasis, and intracellular signaling modulation is unknown. METHODS:Breast cancer cell lines MCF7 and MDA-MB-231 were treated with sorafenib and its effect on proliferation, migration, invasion and gene expression was analyzed. RESULTS: We found that sorafenib has an anti-proliferative and cytotoxic effect on breast cancer cells. Importantly, sorafenib inhibited the migration and invasion of breast cancer cells in vitro. Mechanistically, sorafenib increased mitochondrial superoxide production, suppressed breast cancer stem cell self-renewal, inhibited epithelial mesenchymal transition and ERK signaling. CONCLUSION: Thus, sorafenib has anti-cancer activity against breast cancer cells and could improve the survival of breast cancerpatients by inhibiting their invasive and metastatic properties.
Authors: Aki Morikawa; Milan Grkovski; Sujata Patil; Komal L Jhaveri; Kendrick Tang; John L Humm; Andrei Holodny; Kathryn Beal; Heiko Schöder; Andrew D Seidman Journal: Breast Cancer Res Treat Date: 2021-06-10 Impact factor: 4.872
Authors: Jan-Paul Gundlach; Jannik Kerber; Alexander Hendricks; Alexander Bernsmeier; Christine Halske; Christian Röder; Thomas Becker; Christoph Röcken; Felix Braun; Susanne Sebens; Nils Heits Journal: J Clin Med Date: 2022-05-15 Impact factor: 4.964
Authors: Bruna R Silva; Rita Rebelo; Juliana M Rodrigues; Cristina P R Xavier; M Helena Vasconcelos; Maria-João R P Queiroz Journal: Molecules Date: 2021-03-13 Impact factor: 4.411